Conatus Pharmaceuticals Appoints Dr. Gary Burgess as Senior Vice President and Chief Medical Officer - Gilde Healthcare

Conatus Pharmaceuticals Appoints Dr. Gary Burgess as Senior Vice President and Chief Medical Officer

31. Oktober 2011

SAN DIEGO – Conatus Pharmaceuticals Inc. announced today the appointment of Gary Craig Burgess, M.B., Ch.B. MMed, as Senior Vice President and Chief Medical Officer effective immediately. In this newly created position, Dr. Burgess will oversee all of the company’s clinical development activities.

“I am delighted to welcome Gary to the Conatus leadership team,” said Steven J. Mento, Ph.D., President and CEO. “His broad experience in drug development including fibrotic diseases will be particularly important as we move forward with the development of emricasan, our caspase inhibitor, targeted as a treatment for a variety of fibrotic diseases.”

From 1999 through 2011, Dr. Burgess held various positions of increasing authority at Pfizer Inc. and most recently as Senior Director and Clinical Portfolio Lead for Asia Research. In this position, he had clinical oversight of all aspects of the Pfizer liver fibrosis program including clinical program design, development and execution, regulatory and key opinion leader interactions, and evaluation and establishment of external collaborations for fibrotic disease biomarker development. During the period following the acquisition of Idun Pharmaceuticals by Pfizer, Dr. Burgess’ responsibilities included data integration, clinical oversight of ongoing Phase II studies, development of clinical plans and registration strategies for the Idun caspase inhibitor, IDN-6556, which was later assigned the USAN name emricasan.

“I am impressed by the strong scientific leadership at Conatus,” said Dr. Burgess. “Emricasan has the potential to be a promising treatment for patients with fibrotic diseases of various etiologies, an area of high unmet medical need, and I am enthusiastic and excited about the company’s potential to realize these possibilities.”

Dr. Burgess earned his M.B, Ch.B. and MMed in Internal Medicine degrees or the equivalent of an M.D. in the U.S. from the University of Stellenbosch in South Africa.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics in the areas of fibrotic disease and oncology. Conatus’ lead drug candidate, emricasan (IDN-6556) is in development as a potential therapy for a variety of fibrotic diseases. Fibrotic diseases affect millions of people worldwide and can be caused by many different types of injuries. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. Conatus acquired the Idun subsidiary from Pfizer in 2010.

For additional information, please visit www.conatuspharma.com.

Mehr neuigkeiten

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17. Oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15. Oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14. Oktober 2025